Previous 10 | Next 10 |
home / stock / alxo / alxo articles
U.S. stock futures traded mixed this morning on Wednesday. Here are some big stocks recording losses in today’s pre-market trading session. ...
U.S. stocks extended losses toward the end of trading, with the S&P 500 falling around 1.5% on Tuesday. The Dow traded down 1.43% to 32,95...
Gainers Vericity, Inc. (NASDAQ: VERY) shares climbed 87.4% to $11.12 after iA Financial Group announced it will acquire the company. POINT Biopha...
Benzinga Microsoft's Nadella Criticizes Google's Exclusive Content Deals Amid Antitrust Case In a significant development, Microsoft ...
ALX Oncology Holdings Inc (NASDAQ: ALXO) released prespecified interim Phase 2 data from its ASPEN-06 trial of evorpacept plus trastuzumab, Cy...
Gainers VIQ Solutions Inc. (NASDAQ: VQS) shares rose 88.5% to $0.2470 in pre-market trading after falling 18% on Monday. VIQ Solutions recently a...
Early indications suggest another day of lackluster trading after two months of subdued market activity. Index futures point to a modestly higher...
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), an i...
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology") (NASDAQ:ALXO), a clinical-stage immu...
News, Short Squeeze, Breakout and More Instantly...
ALX Oncology Holdings Inc. Company Name:
ALXO Stock Symbol:
NASDAQ Market:
ALX Oncology Holdings Inc. Website:
2024-07-09 15:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Evorpacept in combination with PADCEV ® , an approved antibody-drug conjugate (“ADC”), demonstrated promising activity and was generally well tolerated Company to host conference call and webcast with Samuel A. Funt, M.D., of Memorial Sloan Kettering Cancer Center on ...
SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced that management wi...